It is the same scenario for previously reported cases of hypocomplementaemic idiopathic immune complex tubulointerstitial nephritis (TBIN) that we mentioned in our case report [1, 2] . In the absence of this evidence, presence or absence of IgG4 disease in reference to our case remains a speculation.
On reviewing the literature of IgG4 disease, we noted some important differences. Most of the cases of IgG4 disease have concurrent or subsequent systemic involvement [3] . On the contrary, there was no evidence of systemic or extrarenal disease in our case even after a follow-up of 18 months [1] . In the largest reported series of cases of hypocomplementaemic idiopathic immune complex TBIN by Kambham et al., there were two cases of sclerosing cholangitis which could be potentially indicative of IgG4 disease [2] . However, autoimmune pancreatitis, which is one of the most commonly reported features of IgG4 disease, was conspicuous by its absence in all the reported cases of idiopathic TBIN [1] [2] [3] . Also, no significant glomerular disease has been reported in cases of idiopathic TBIN, while membranous and membranoproliferative glomerulonephritis have been reported with IgG4 disease [1, 2, 4, 5] . We could not find any reported case of IgG4 disease with tubulointerstitial nephritis and no extrarenal involvement. There are cases described without pancreatitis, but even they have some extrarenal involvement in terms of sialadenitis and lymphadenopathy [6] .
In conclusion, it is difficult to say whether our case has IgG4 disease as aetiology due to lack of IgG4 levels and tissue staining and in the light of available literature. (20), amodiaquine (13), mefloquine (7), piperaquine/triméthoprim (6)] treatment for malaria were retrospectively studied (Table 1) . Concomitant prescribed drugs included quinine (33) and paracetamol (16). All patients were admitted for acute hepatorenal failure under treatment (median time, 2 days), and half of them required haemodialysis (1.7 ± 2.1 sessions). The ABC treatment was withdrawn on admission for all. Twelve patients (26%, Group 1) died, and 34 patients (74%, Group 2) recovered within a median of 3 and 12 days from admission, respectively (Table 1) . Comparison of variables between the treated groups was done using Student's t-test. Of the patients alive, renal improvement was confirmed after a 3-month follow-up (mean serum creatinine 1.5 mg/dL).
The case fatality rate in severe malaria treated with either quinine or artemisinin can be expected to be 10-25% even under optimal conditions [4]. However, whether malaria and/or drug side effects are causes of acute hepatorenal failure (AHRF) in our study is unclear. Multiple antimalarial drugs, normal temperature and negative malarial blood film as well as bacteriological investigations on admission plead for an iatrogenic effect rather than a progression of the infectious illness. The mechanism underlying this severe complication remains to be established. Only the presence of coma on admission was found to be an independent risk factor of mortality in our cohort (P = 0.0006) ( Table 1 ). The potential neurological toxicity of an artemisinin-based treatment has already been suspected in both animal and human studies. When administered daily in high doses to dogs and rats, artemether and arteether caused neuropathic lesions in the caudal brain stem [5] . In randomized clinical trials, coma associated with increased incidence of convulsions (39% vs. 28%, P = 0.01) was significantly prolonged [1, 2] in the artemether group [1], indicating the need for an active investigation of the neurologic side effects of these drugs.
We believe practitioners in tropical health centres should be aware of such complication, and an active investigation of the neurological side effects is needed. In case of inefficient initial treatment, documenting malarial infection is necessary before starting a multimolecular therapy. 
